Thymus Cancer - Pipeline Review, H2 2015

Date: December 9, 2015
Pages: 95
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: TE7DB67B9CDEN
Leaflet:

Download PDF Leaflet

Thymus Cancer - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Thymus Cancer - Pipeline Review, H2 2015’, provides an overview of the Thymus Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thymus Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thymus Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Thymus Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Thymus Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Thymus Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Thymus Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Thymus Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Thymus Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Thymus Cancer Overview
Therapeutics Development
Pipeline Products for Thymus Cancer - Overview
Pipeline Products for Thymus Cancer - Comparative Analysis
Thymus Cancer - Therapeutics under Development by Companies
Thymus Cancer - Therapeutics under Investigation by Universities/Institutes
Thymus Cancer - Pipeline Products Glance
Clinical Stage Products
Thymus Cancer - Products under Development by Companies
Thymus Cancer - Products under Investigation by Universities/Institutes
Thymus Cancer - Companies Involved in Therapeutics Development
Cellceutix Corporation
Merck & Co., Inc.
Novartis AG
Onxeo SA
Sumitomo Dainippon Pharma Co., Ltd.
Tiziana Life Sciences Plc
Thymus Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
amrubicin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
belinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cellular Immunotherapy 2 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KM-3174 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-2206 + selumetinib sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pasireotide LAR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thymus Cancer - Recent Pipeline Updates
Thymus Cancer - Product Development Milestones
Featured News & Press Releases
Aug 11, 2015: Cellceutixs Kevetrin and Thymoma — a Rare Cancer
Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014
May 14, 2014: Phase II data of Nerviano Medical Science’s kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO
Jul 18, 2013: Belinostat gets European orphan drug designation for the treatment of malignant thymomas
May 17, 2012: Topotarget Presents Phase I/II Clinical Data Of Belinostat At ASCO 2012
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Thymus Cancer, H2 2015
Number of Products under Development for Thymus Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Thymus Cancer - Pipeline by Cellceutix Corporation, H2 2015
Thymus Cancer - Pipeline by Merck & Co., Inc., H2 2015
Thymus Cancer - Pipeline by Novartis AG, H2 2015
Thymus Cancer - Pipeline by Onxeo SA, H2 2015
Thymus Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Thymus Cancer - Pipeline by Tiziana Life Sciences Plc, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Thymus Cancer Therapeutics - Recent Pipeline Updates, H2 2015

LIST OF FIGURES

Number of Products under Development for Thymus Cancer, H2 2015
Number of Products under Development for Thymus Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

COMPANIES MENTIONED

Cellceutix Corporation
Merck & Co., Inc.
Novartis AG
Onxeo SA
Sumitomo Dainippon Pharma Co., Ltd.
Tiziana Life Sciences Plc
Skip to top


Colorectal Cancer - Pipeline Review, H2 2015 US$ 2,125.00 Dec, 2015 · 1511 pages
Prostate Cancer - Pipeline Review, H2 2015 US$ 2,125.00 Dec, 2015 · 1596 pages

Ask Your Question

Thymus Cancer - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: